Genprex, Inc.

@genprex

Genprex's (GNPX) lead candidate Oncoprex™ uses immunogene therapy and nanotechnology to help defeat cancer.

Austin, TX
Vrijeme pridruživanja: srpanj 2016.

Tweetovi

Blokirali ste korisnika/cu @genprex

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @genprex

  1. prije 21 sat

    Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

    Poništi
  2. 4. velj

    Help us raise awareness of cancer prevention, detection and treatment for all cancer patients and their families.

    Poništi
  3. 3. velj

    Genprex to Present at NobleCon16 Investor Conference

    Poništi
  4. 1. velj

    In some cases, cancer can be prevented with a few lifestyle changes. Another way to prevent cancer is through genetic testing.

    Poništi
  5. 30. sij

    Dr. Pasi Jänne is at it again. Read his blog post, titled "Scientists Reveal How Lung Cancer Cells Avoid Death from Targeted Drugs"

    Poništi
  6. 29. sij

    Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy

    Poništi
  7. 28. sij

    Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering

    Poništi
  8. 27. sij

    Watch CEO Rodney Varner discuss with Proactive the company's recent FDA Fast Track Designation and capital raise:

    Poništi
  9. 27. sij

    A new study suggests that active patients undergoing chemotherapy may experience greater success in their treatment. Read more:

    Poništi
  10. 23. sij

    FDA Grants Fast Track Designation to Gene Therapy Combination in EGFR-Mutant NSCLC

    Poništi
  11. 23. sij

    FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

    Poništi
  12. 23. sij

    Genprex Wins FDA Fast Track Status for its Oncoprex Therapy in Combination with AstraZeneca’s Tagrisso

    Poništi
  13. 23. sij

    Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market

    Poništi
  14. 23. sij

    Learn more about Fast Track Designation:

    Poništi
  15. 22. sij

    featured in Targeted Oncology for FDA Fast Track Designation. Read more:

    Poništi
  16. 22. sij

    Read more about Fast Track Designation:

    Poništi
  17. 21. sij

    Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer

    Poništi
  18. 20. sij

    Today we honor and remember Dr. Martin Luther King, Jr.

    Poništi
  19. 17. sij

    Genprex's current research strategy, including its targeted therapy research for EGFR mutations and its immunotherapy research with checkpoint inhibitors, is on trend with lung cancer research seen by a Stanford oncology professor. Read more:

    Poništi
  20. 15. sij

    New data on cancer deaths show a large decline in recent years. Read more:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·